X

    Xenetic Biosciences Inc (XBIO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.19
    +0.21 (+5.28%)

    Market Cap: $9.33M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    63%(19/30)
    Avg Surprise
    -62.73%
    Streak
    4 Q
    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    		$-0.41N/AN/ABeat+8.9%
    Mar 26
    		$-0.20N/AN/ABeat+66.2%
    Dec 25
    		$-0.22N/A+57.69%Beat+67.6%
    Sep 25
    		$-0.33$-0.49+32.65%Beat-17.9%
    Jun 25
    		$-0.45$-0.64+29.69%Beat+45.8%
    Mar 25
    		$-0.59$-0.72+18.06%Beat+24.4%
    Dec 24
    		$-0.68$-0.20-240.00%Miss+11.7%
    Sep 24
    		$-0.28$-0.14-100.00%Miss+59.4%
    Jun 24
    		$-0.83$-0.83+0.00%Beat-20.3%
    Mar 24
    		$-0.78$-0.79+1.27%Beat-30.0%
    Dec 23
    		$-0.77$-0.87+11.49%Beat-670.0%
    Sep 23
    		$-0.69$-1.12+38.39%Beat-15.0%
    Jun 23
    		$-0.69$-1.13+38.94%Beat+63.7%
    Mar 23
    		$-0.60$-1.10+45.45%Beat+50.0%
    Dec 22
    		$-0.10$-0.09-11.11%Miss+28.6%
    Sep 22
    		$-0.60N/A+66.67%Beat+53.8%
    Jun 22
    		$-1.90$-1.20-58.33%Miss-46.2%
    Mar 22
    		$-1.20$-1.10-9.09%Miss+20.0%
    Dec 21
    		$-0.14$-0.15+6.67%Beat+12.5%
    Sep 21
    		$-1.30$-1.20-8.33%Miss+8.5%
    Jun 21
    		$-1.30$-1.60+18.75%Beat+13.3%
    Mar 21
    		$-1.50$-1.30-15.38%Miss+21.1%
    Dec 20
    		$-0.16$-0.20+20.00%Beat+20.0%
    Sep 20
    		$-1.42$-1.30-9.23%Miss+46.8%
    Jun 20
    		$-1.50$-2.20+31.82%Beat-476.9%
    Mar 20
    		$-1.90$-3.70+48.65%Beat-630.8%
    Dec 19
    		$-0.20$-0.38+47.37%Beat+90.4%
    Sep 19
    		$-2.67N/AN/ABeat-926.9%
    Jun 19
    		$-0.26N/AN/ABeat+0.0%
    Mar 19
    		$-0.26N/AN/ABeat+0.0%
    Dec 18
    		$-2.09N/AN/ABeat-704.5%
    Sep 18
    		$-0.26N/AN/ABeat+99.2%
    Jun 18
    		$-0.26N/AN/ABeat+99.4%
    Mar 18
    		$-0.26$0.00N/ABeat+99.4%
    Dec 17
    		$-0.26$0.00N/ABeat+96.2%
    Sep 17
    		$-31.20$-49.20+36.59%Beat-796.6%
    Jun 17
    		$-40.80$-46.80+12.82%Beat-
    Mar 17
    		$-40.80$-25.20-61.90%Miss-
    Dec 16
    		$-6.84$-2.28-200.00%Miss-
    Sep 16
    		$-3.48$-0.19-1731.58%Miss-

    Key Metrics

    Valuation
    P/E Ratio-3.61EV/EBITDA1.03x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-75.90%Operating Margin-147.10%
    ROE-47.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio7.43xQuick Ratio7.43x
    Trading Statistics
    Beta2.15Avg Volume72.96K
    52-Week High$13.9352-Week Low$1.90

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.72
    SMA 20$3.42
    SMA 50$3.03
    SMA 200$2.77
    EMA 10$3.77
    EMA 20$3.50
    EMA 50$3.20
    EMA 200$3.01

    MACD

    Line: 0.31Signal: 0.23Hist: 0.08

    ADX

    ADX: 46.0+DI: 40.2-DI: 4.6

    Aroon & PSAR

    Aroon Up100.0
    Aroon Down4.0
    PSAR$3.72

    Bollinger Bands

    Upper Band$4.21
    Lower Band$2.63
    %B Position4623%(Upper)
    Band Width0.98

    RSI (14-Day)

    Overbought
    84.1

    Momentum Oscillators

    Stoch %K91.7
    Stoch %D89.3
    Williams %R-9.2
    ROC (10d)28.5%
    Momentum0.93
    CCI (20d)157.9
    MFI (14d)86.3

    Volatility Measures

    ATR (14d)$0.22(5.3%)
    StdDev (20d)0.40
    Hist Vol56.6%(High)

    Volume Flow

    VWAP$4.15
    OBV47.9M
    AD Line-27.4M
    CMF (20d)0.529

    Volume Metrics

    Avg Vol (20d)70.2K
    Vol Ratio0.4x(Low)
    VWMA (20d)$3.29

    Pivot Points

    R3$4.22
    R2$4.14
    R1$4.06
    Pivot Point$3.98
    S1$3.90
    S2$3.82
    S3$3.74

    Advanced Oscillators

    TSI50.36
    Ultimate Osc72.7
    KST324.93

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$660,601$806,923$766,296$1.03M$589,897$593,261$648,820$614,243$726,404$510,816$671,963$611,174
    Cost of RevenueN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
    Gross Profit$660,601$806,923$766,296$1.03M$589,897$593,261$648,820$614,243$726,404$510,816$671,963$611,174
    Operating Expenses$1.63M$1.31M$1.39M$1.57M$1.31M$1.54M$1.75M$1.11M$2.06M$1.78M$1.93M$1.76M
    R&D$552,013$661,443$773,416$756,482$656,557$879,029$1.04M$367,985$933,771$944,321$975,628$1.02M
    SG&A$1.08M$647,597$615,907$815,209$657,752$656,641$705,710$745,731$1.13M$834,910$952,002$737,241
    Operating Income$-971,690$-502,117$-623,027$-544,734$-724,412$-942,409$-1,099,145$-499,473$-1,337,396$-1,268,414$-1,255,670$-1,146,685
    Interest Income$42,067$45,756$43,792$30,783$34,232$39,190$51,867$61,298$63,447$73,249$83,757$91,796
    Interest Expense$0$0$0$0$0$0$0$0$0$58,621$58,621$0
    Income Before Tax$-929,695$-456,382$-579,076$-509,939$-688,703$-903,141$-1,054,521$-436,671$-1,273,970$-1,195,113$-1,171,506$-1,055,555
    Income Tax Expense$0$0$0$0$0$-10,624$0$-436,671$-18,980$10,624$7,849$-99,436
    Net Income$-929,695$-456,382$-579,076$-509,939$-688,703$-903,141$-1,054,521$-436,671$-1,273,970$-1,195,113$-1,171,506$-1,055,555
    EBITDA$-929,695$-456,382$-579,076$-509,939$-688,703$-903,141$-1,099,145$-436,671$-1,273,970$-1,195,113$-1,255,670$-1,047,915
    EBITN/AN/AN/A$-509,939N/A$-1,109,769N/AN/A$-1,356,380$-1,268,414$-1,299,482$-1,055,555
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about XBIO

    News

    Xenetic Biosciences, Inc. Revenue Breakdown – NASDAQ:XBIO

    This article provides a revenue breakdown for Xenetic Biosciences, Inc. (NASDAQ: XBIO), highlighting the company's financial performance. It indicates that the United States was the primary contributor to its revenue, generating $2.98 million last year, an increase from $2.50 million the previous year. The content focuses solely on these financial figures without further analysis or additional details.

    TradingView•8/22/26•
    Neutral

    Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform

    Xenetic Biosciences announced its second-quarter 2026 financial results, emphasizing continued progress with its proprietary DNase platform. The company reported a 12% increase in royalty revenue due to a sublicense agreement with Takeda Pharmaceuticals, while R&D expenses decreased and G&A expenses rose due to legal costs for strategic review. Xenetic highlighted positive preclinical data for DNase I in enhancing CAR T-cell therapies and a new collaboration for an investigator-initiated study in large B-cell lymphoma.

    Yahoo Finance•8/7/26•
    Bullish

    Xenetic Biosciences reports Q2 2026: $0.7M royalty revenue, $0.9M quarterly net loss

    Xenetic Biosciences reported its Q2 2026 financial results, showing approximately $0.7 million in royalty revenue and a net loss of $0.9 million. The company ended the quarter with $6.5 million in cash and highlighted expanded translational research and collaborations for its DNase platform. Business advancements include positive preclinical data presentations and partner approvals for an exploratory study.

    TradingView•8/7/26•
    Neutral

    Xenetic partner receives Israeli approvals for lymphoma study

    Xenetic Biosciences reported its Q2 2026 financial results, highlighting approximately $0.7 million in royalty revenue and a net loss of $0.9 million. The company announced that its collaboration partner, PeriNess Ltd., received Israeli regulatory approvals to conduct an exploratory study of DNase I in combination with CAR T-cell therapy for large B-cell lymphoma. Xenetic continues to advance its proprietary DNase platform, focusing on enhancing existing cancer therapies by targeting neutrophil extracellular traps.

    Stock Titan•8/7/26•
    Somewhat-Bullish

    Xenetic Biosciences, Inc. 2026: Revenue $660.6K, EPS ($0.41) — 10-Q Summary

    Xenetic Biosciences, Inc. (XBIO) reported its 2026 quarterly results with revenue of $660.6K, a 12% increase year-over-year, and a diluted loss per share of ($0.41). The company's net loss was ($929.7K), an increase of 35% from the prior year quarter. Revenue growth was primarily driven by royalty income from a Takeda sublicense, while R&D spending decreased.

    TradingView•8/6/26•
    Somewhat-Bearish

    Frequently Asked Questions About XBIO

    Does XBIO pay dividends?
    Xenetic Biosciences Inc (XBIO) does not currently pay a regular dividend.
    What is XBIO's market cap?
    Xenetic Biosciences Inc (XBIO) has a market capitalization of $9.33M with a current stock price of $4.19.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In